Combined diphtheria-tetanus-whole cell pertussis, hepatitis B vaccine and Haemophilus influenzae type b vaccine (KFT) studies
Select the study ID number to view the trial summary
| Study ID | Phase | Title |
| 101223 (DTPW-HBV=HIB KFT-002) | III | Phase III, multi-country, randomised, controlled, partially-blind study to assess the lot-to-lot consistency of the production method of GlaxoSmithKline Biologicals’ DTPw-HBV/ Hib Kft. vaccine and to compare to GlaxoSmithKline Biologicals’ Tritanrix™-HepB/Hiberix™ vaccine, when administered as a primary vaccination course to healthy infants at 2, 4 and 6 months of age and co-administered with oral live attenuated poliomyelitis vaccine. Tritanrix™-HepB/Hiberix™ (DTPw-HBV/Hib): GlaxoSmithKline (GSK) Biologicals’ combined diphtheria, tetanus, whole cell Bordetella pertussis, hepatitis B and Haemophilus Influenzae type b vaccine. DTPw-HBV/Hib Kft vaccine (DTPw-HBV/ Hib Kft.) is GlaxoSmithKline (GSK) Biologicals’ combined diphtheria, tetanus, whole cell Bordetella pertussis, hepatitis B and Haemophilus Influenzae type b vaccine produced at GSK Biologicals Kft., Gödöllö, Hungary. GSK Biologicals’ licensed trivalent Oral Polio Vaccine (OPV) - Polio Sabin™, was co-administered along with the DTPw containing vaccines. |
| 104065 (DTPW-HBV=HIB KFT-003) | III | A phase III, open, randomised study to assess the immune memory following primary vaccination with GlaxoSmithKline (GSK) Biologicals’ DTPw-HBV/Hib Kft. vaccine by giving Plain PRP polysaccharide vaccine at 10 months of age, and to assess the immunogenicity and reactogenicity of a booster dose of GSK Biologicals’ DTPw-HBV/Hib Kft. vaccine or DTPw-HBV Kft. vaccine given alone or the concomitant administration of DTPw-HBV Kft. and Hiberix™ vaccines, at 15-18 months of age in subjects primed in study DTPw-HBV=Hib Kft-001. DTPw-HBV/Hib Kft.: GlaxoSmithKline (GSK) Biologicals Korlatolt Felelossegu Tarsasag [Kft] (Limited Company) combined diphtheria (D), tetanus (T), whole cell Bordetella pertussis (Pw), hepatitis B vaccine with new sources of D, T and Pw antigens mixed with Haemophilus influenzae type b (Hib2.5) vaccine. Polyribosil-Ribitol-Phosphate (PRP): plain PRP polysaccharide vaccine DTPw-HBV Kft.: GSK Biologicals Korlatolt Felelossegu Tarsasag [Kft] (Limited Company) combined diphtheria, tetanus, whole cell Bordetella pertussis, hepatitis B vaccine with new sources of D, T and Pw antigens produced at GSK Biologicals Kft., Gödöllö, Hungary. Hiberix™ (Hib): GSK Biologicals’ Haemophilus influenzae type b vaccine. |
| 104489 (DTPW-HBV=HIB KFT-004) | III | A phase III, partially double-blind, randomized study to evaluate the immunogenicity, safety and reactogenicity of GlaxoSmithKline (GSK) Biologicals Kft’s DTPwGod-HBV/Hib Kft. vaccine as compared to GSK Biologicals Kft’s DTPwCSL-HBV/Hib Kft. vaccine and to the concomitant administration of CSL’s Triple Antigen™ and GSK Biologicals’ Hiberix™ vaccine, when administered to healthy infants at 2, 4 and 6 months of age, after a birth dose of hepatitis B vaccine. DTPwGod-HBV/Hib Kft.: combined diphtheria-tetanus-whole cell Bordetella pertussis-hepatitis B vaccine mixed with Haemophilus influenzae type b vaccine developed and manufactured by GSK Biologicals Kft., Gödöllö, Hungary. DTPwCSL-HBV/Hib Kft.: combined diphtheria-tetanus-whole cell Bordetella pertussis-hepatitis B vaccine mixed with Haemophilus influenzae type b vaccine developed and manufactured by GSK Biologicals Kft., Gödöllö, Hungary in co-operation with Commonwealth Serum Laboratory (CSL), Australia. Triple Antigen™: CSL’s combined diphtheria-tetanus-whole cell Bordetella pertussis (DTPwCSL) vaccine. Hiberix™: GSK Biologicals’ Haemophilus influenzae type b vaccine. |
| 106602 (DTPw-HBV=Hib-Kft-006) | III | A phase III, open, multicentric, clinical study to assess the immunogenicity, reactogenicity and safety of a booster dose of GlaxoSmithKline (GSK) Biologicals combined DTPw-HBV/Hib Kft. vaccine as compared to GSK Biologicals’ Tritanrix™-HepB/Hiberix™ vaccine, when administered to healthy infants between 18 and 24 months of age, who have received a three-dose primary immunization course with the same vaccines as in study DTPw-HBV=Hib Kft-002 (101223). DTPw-HBV/Hib Kft.: GlaxoSmithKline (GSK) Biologicals’ combined diphtheria-tetanus-whole cell Bordetella pertussis-hepatitis B vaccine mixed with Haemophilus influenzae type b low-dose vaccine with the D, T and Pw components produced by GSK Biologicals, Gödöllö. Tritanrix™-HepB/Hiberix™ (DTPw-HBV/Hib): GSK Biologicals’ combined diphtheria-tetanus-whole cell Bordetella pertussis-hepatitis B vaccine, mixed with Haemophilus influenzae type b conjugate vaccine. |
| 101222 (DTPw-HBV=Hib Kft-001) | II | Phase III, partially blinded, randomized, controlled, primary vaccination study to demonstrate the non-inferiority of GlaxoSmithKline (GSK) Biologicals’ DTPw-HBV/Hib Kft. vaccine compared to GSK Biologicals’ Tritanrix™-HepB/Hiberix™ vaccine and to separate administration of DTPw-HBV Kft. and Hiberix™ vaccines with respect to the immunogenicity of all antigens, when administered to healthy infants at 6, 10 and 14 weeks of age. The immunogenicity of GSK Biologicals’ DTPw-HBV/Hib Kft. administered after a birth dose of Hepatitis B vaccine will also be assessed. Tritanrix™-HepB/Hiberix™ (DTPw-HBV/Hib): combined diphtheria, tetanus, whole cell Bordetella pertussis, hepatitis B and Haemophilus Influenzae type b vaccine DTPw-HBV/Hib Kft.: GSK Biologicals’ combined diphtheria, tetanus, whole cell Bordetella pertussis, hepatitis B and Haemophilus Influenzae type b vaccine produced at GSK Biologicals Kft., Gödöllö, Hungary. DTPw-HBV Kft.: GSK Biologicals’ combined diphtheria, tetanus, whole cell Bordetella pertussis and hepatitis B vaccine produced at GSK Biologicals Kft., Gödöllö, Hungary. Hiberix™: GSK Biologicals’ Haemophilus Influenzae type b vaccine |